Crossmark

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

Crossref DOI link: https://doi.org/10.1186/s12943-018-0840-y

Published Online: 2018-05-16

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pang, Yanyu

Hou, Xiaoyang

Yang, Chunsheng

Liu, Yanqun

Jiang, Guan http://orcid.org/0000-0003-0377-9112
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No.81572976)

China Postdoctoral Science Foundation (Nos.2016M590505, 2017T100407)

Postgraduate Research & Practice Innovation Program of Jiangsu Province (No. KYCX17_1715, No. KYCX17_1718)
License Information

Text and Data Mining valid from 2018-05-16
More Information

Article History

Received: 11 January 2018

Accepted: 2 May 2018

First Online: 16 May 2018

Ethics approval and consent to participate

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.